Medical application of functionalized magnetic nanoparticles

被引:1241
作者
Ito, A
Shinkai, M
Honda, H
Kobayashi, T
机构
[1] Chubu Univ, Sch Biosci & Biotechnol, Kasugai, Aichi 4878501, Japan
[2] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan
[3] Nagoya Univ, Sch Engn, Dept Biotechnol, Chikusa Ku, Nagoya, Aichi 4648603, Japan
关键词
magnetic nanoparticle; magnetic resonance imaging; hyperthermia; drug delivery system; tissue engineering;
D O I
10.1263/jbb.100.1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Since magnetic particles have unique features, the development of a variety of medical applications has been possible. The most unique feature of magnetic particles is their reaction to a magnetic force, and this feature has been utilized in applications such as drug targeting and bioseparation including cell sorting. Recently, magnetic nanoparticles have attracted attention because of their potential as contrast agents for magnetic resonance imaging (MRI) and heating mediators for cancer therapy (hyperthermia). Magnetite cationic liposomes (MCLs), one of the groups of cationic magnetic particles, can be used as carriers to introduce magnetite nanoparticles into target cells since their positively charged surface interacts with the negatively charged cell surface; furthermore, they find applications to hyperthermic treatments. Magnetite nanoparticles conjugated with antibodies (antibody-conjugated magnetoliposomes, AMLs) are also applied to hyperthermia and have enabled tumor-specific contrast enhancement in MRI via systemic administration. Since magnetic nanoparticles are attracted to a high magnetic flux density, it is possible to manipulate cells labeled with magnetic nanoparticles using magnets; this feature has been applied in tissue engineering. Magnetic force and MCLs were used to construct multilayered cell structures and a heterotypic layered 3D coculture system. Thus, the applications of these functionalized magnetic nanoparticles with their unique features will further improve medical techniques.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 83 条
  • [1] [Anonymous], 1994, JPN J HYPERTHERMIC O
  • [2] HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine
    Asea, A
    Kraeft, SK
    Kurt-Jones, EA
    Stevenson, MA
    Chen, LB
    Finberg, RW
    Koo, GC
    Calderwood, SK
    [J]. NATURE MEDICINE, 2000, 6 (04) : 435 - 442
  • [3] BARCLAY AN, 1993, LEUKOCYTES ANTIGEN
  • [4] CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
    Basu, S
    Binder, RJ
    Ramalingam, T
    Srivastava, PK
    [J]. IMMUNITY, 2001, 14 (03) : 303 - 313
  • [5] LIVING TISSUE FORMED INVITRO AND ACCEPTED AS SKIN-EQUIVALENT TISSUE OF FULL THICKNESS
    BELL, E
    EHRLICH, HP
    BUTTLE, DJ
    NAKATSUJI, T
    [J]. SCIENCE, 1981, 211 (4486) : 1052 - 1054
  • [6] Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings
    Belli, F
    Testori, A
    Rivoltini, L
    Maio, M
    Andreola, G
    Sertoli, MR
    Gallino, G
    Piris, A
    Cattelan, A
    Lazzari, I
    Carrabba, M
    Scita, G
    Santantonio, C
    Pilla, L
    Tragni, G
    Lombardo, C
    Arienti, F
    Marchianò, A
    Queirolo, P
    Bertolini, F
    Cova, A
    Lamaj, E
    Ascani, L
    Camerini, R
    Corsi, M
    Cascinelli, N
    Lewis, JJ
    Srivastava, P
    Parmiani, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4169 - 4180
  • [7] Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications
    Bergemann, C
    Müller-Schulte, D
    Oster, J
    à Brassard, L
    Lübbe, AS
    [J]. JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 1999, 194 (1-3) : 45 - 52
  • [8] Bhatia SN, 1997, J BIOMED MATER RES, V34, P189, DOI 10.1002/(SICI)1097-4636(199702)34:2<189::AID-JBM8>3.0.CO
  • [9] 2-M
  • [10] CAVALIER.R, 1967, CANCER, V20, P1351, DOI 10.1002/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO